Marius Hoeper, MD, discusses the direct medical costs and indirect socioeconomic costs associated with the treatment of pulmonary arterial hypertension (PAH), including hospitalizations, outpatient care, and patient productivity and quality of life.
Video content above is prompted by the following questions:
PAH Therapies Improve Outcomes in PH-ILD
March 26th 2025Pulmonary hypertension is a common consequence of interstitial lung disease (PH-ILD), with the highest rate seen among individuals who have idiopathic pulmonary fibrosis. Overall, most cases of PH in the setting of ILD are mild.
Read More
Lorundrostat Significantly Lowers Blood Pressure in Key Hypertension Trials
March 24th 2025New topline data from the Launch-HTN (NCT06153693) and Advance-HTN (NCT06153693) clinical trials show these investigations met their primary end points os statistically significant reductions in systolic blood pressure.
Read More
Pulmonary Hypertension Subtypes Show Distinct PA Flow Hemodynamics
March 21st 2025Investigators used 4D flow cardiovascular magnetic resonance imaging to search for differences between pulmonary artery (PA) remodeling in pulmonary arterial hypertension and other types of pulmonary hypertension.
Read More
Managing Pulmonary Hypertension in Pregnancy
March 18th 2025Pulmonary arterial hypertension (PAH) can be a challenging complication to manage during pregnancy; women with PAH who are pregnant are considered a high-risk population, and they face higher rates of maternal and fetal complications.
Read More
PAH Treatment Benefits Extend to Patients With Repaired Congenital Heart Disease
March 14th 2025Historical data show the prevalence of pulmonary arterial hypertension (PAH) in adult patients with congenital heart disease ranges from 4% to 28%, according to studies from the US and Europe—and that the prevalence of these comorbid condition is on the rise.
Read More